Navigation Links
Baxter and The Alzheimer's Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimer's Disease
Date:8/28/2007

n Relkin and his colleagues at Weill Cornell Medical College in New York City. In this study, 24 patients with mild to moderate Alzheimer's disease were randomly assigned to receive GAMMAGARD Liquid, GAMMAGARD S/D or placebo (eight patients were treated with GAMMAGARD Liquid, eight patients were treated with GAMMAGARD S/D and eight patients received placebo) for six months. Cognitive, behavioral and functional measures were collected at baseline, three months and six months of treatment. The primary endpoints of the Phase II trial were cognitive function (as measured by ADAS-Cog score) and global function (as assessed by ADCS-CGIC rating). The pre-specified criterion for going forward with Phase III was a favorable outcome in IGIV-treated patients relative to those given placebo. Final results of the analysis of the Phase II study are expected later this year.

The Phase II study follows Dr. Relkin's earlier Phase I results in eight patients that were reported at the International Conference on Alzheimer's Disease in Madrid in July, 2006. Although these findings are promising, both studies were small and results must therefore be confirmed in a larger, sufficiently powered study.

The study protocol will be submitted to the U.S. Food and Drug Administration for review in the coming months with the intention of initiating patient recruitment early in 2008. The ADCS Phase III trial is sponsored jointly by the National Institutes of Health and Baxter. The trial will include approximately 35 leading academic centers in the U.S. that are members of ADCS.

GAMMAGARD LIQUID

[Immune Globulin Intravenous (Human)] 10%

GAMMAGARD LIQUID is indicated for the treatment of primary immunodeficiency disorders associated with defects in humoral immunity. These include but are not limited to congenital X-linked agammaglobulinemia, common variable immunodeficiency, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.

Important Safety Inform
'/>"/>

SOURCE Baxter International Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Baxter Presents Phase I Inhaled Insulin Study Results at Respiratory Drug Delivery Conference
2. Baxter Announces Final Phase I/II Data and Initiation of Phase III Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine
3. Cortex Area Thinner in Youth with Alzheimers-Related Gene
4. Appendicitis: Evolving Tools to Diagnose a Classic Disease
5. Non-Invasive Diagnostic Tests for Celiac Disease
6. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. Samaritans Alzheimers Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimers Disease
9. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
10. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
11. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... , April 30, 2015 /PRNewswire/ - Pivotal Therapeutics ... company with a focus on Omega-3 therapies for ... operational highlights and financial results for the fiscal ... referenced herein are in Canadian dollars unless otherwise ... been significant, with the right strategic partners and ...
(Date:4/30/2015)... April 30, 2015  Tandem Diabetes Care ® , Inc. ... of the t:slim ® and t:flex™ Insulin Pumps, today ... 2015. In comparing the first quarter of ... grew 53 percent to $12.3 million from $8.1 million ... from 1,723 pumps "Our investment in resources to ...
(Date:4/30/2015)... 30, 2015  Nektar Therapeutics (Nasdaq: NKTR ) ... ended March 31, 2015. Cash and ... $325.8 million as compared to $262.8 million at December ... at March 31, 2015 includes a $100.0 million milestone ... first commercial sale of Movantik™(naloxegol) in the U.S. ...
Breaking Medicine Technology:Pivotal Therapeutics Announces 2014 Financial Results 2Pivotal Therapeutics Announces 2014 Financial Results 3Pivotal Therapeutics Announces 2014 Financial Results 4Pivotal Therapeutics Announces 2014 Financial Results 5Pivotal Therapeutics Announces 2014 Financial Results 6Tandem Diabetes Care Reports First Quarter 2015 Financial Results 2Tandem Diabetes Care Reports First Quarter 2015 Financial Results 3Tandem Diabetes Care Reports First Quarter 2015 Financial Results 4Tandem Diabetes Care Reports First Quarter 2015 Financial Results 5Tandem Diabetes Care Reports First Quarter 2015 Financial Results 6Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 2Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 3Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 4Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 5Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 6Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 7Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 8Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 9Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 10Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 11Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 12
... voluntary recall of ALL lots of its Ketorolac Tromethamine Injection, USP ... NDC# 0517-0601-25 15 mg/mL ... This recall is in addition to the voluntary recall initiated on ... unexpired lots of Ketorolac Tromethamine Injection, USP, 30 mg/mL ...
... a next-generation oncology diagnostics company focused on improving ... closed a $21 million series A financing. ... and included Bessemer Venture Partners, Physic Ventures and ... ) , On-Q-ity is developing diagnostics to determine ...
Cached Medicine Technology:American Regent Expands Voluntary Recall to Include All Lots of Ketorolac Tromethamine Injection, USP 15 mg/mL; 1mL Single Dose Vials 2Cancer Diagnostics Company, On-Q-ity, Raises $21M in Series A Funding for the Development of Technologies to Personalize Cancer Therapy 2
(Date:5/2/2015)... 02, 2015 ZoomCare, the Portland-based innovator ... plans to offer its new healthcare insurance to individuals ... Personal Health Insurance System is the nation’s first health ... human performance. ZOOM+ Personal Health Insurance was ZoomCare’s first ... that are subject to review and regulation by the ...
(Date:5/1/2015)... IDLife LLC, a health and wellness ... the addition of its newest partner and fitness celebrity, ... athlete, growing up in gymnastics and competitive diving, but ... a personal trainer and helping others achieve their fitness ... TV shows highlighting her stunning physique and unique training ...
(Date:5/1/2015)... 01, 2015 Pioneer Millworks, the largest ... latest in their reclaimed wood products at the 27th ... Javits Center in NYC this May. Their newest offerings, ... much anticipated texture and color to North America's platform ... of texture and color in the design world and ...
(Date:5/1/2015)... ME (PRWEB) May 01, 2015 Royal ... in Freeport, Maine, reports on a new study that ... stiffness, joint swelling and improved physical function as well ... with severe osteoarthritis of the knee. , The report ... Natural Insights for Well Being® ,” which Royal River ...
(Date:5/1/2015)... 01, 2015 TROY Healthcare Solutions is ... Regional User Group (RUG) Conference in Atlanta, GA from ... User Group Conference provides a forum for client-to-client presentations, ... all aspects of electronic medical record operations, as well ... applications. , In addition to sponsoring the event, TROY ...
Breaking Medicine News(10 mins):Health News:ZoomCare Applies to be on Oregon Exchange 2Health News:IDLife LLC Announces New Partnership with Fitness Celebrity, Jen Widerstrom 2Health News:Intensely Textured Reclaimed Wood to be Unveiled at ICFF in NYC by Pioneer Millworks 2Health News:Intensely Textured Reclaimed Wood to be Unveiled at ICFF in NYC by Pioneer Millworks 3Health News:New Study Finds Nutrients Ease Arthritis Pain, Retailer Reports 2Health News:TROY Healthcare to Exhibit at the Cerner Southeast Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner Southeast Regional User Group Conference 3
... stress may take a toll on your heart, researchers say, ... in long hours at work increase their risk of dying ... In fact, people who work three or more hours of ... heart-related problems such as dying from heart disease, having a ...
... ... manager spends up to 40% of the workweek addressing employee conflict? Conflict ... a new chord by providing a resource for managers to outsource their ... the equivalent of up to two (2) business days a week worth ...
... ... Interpretive Dance Video. , ... Seattle, WA (PRWEB) May 11, 2010 -- Onlineshoes.com is proud to announce the ... featuring an interpretive dance video. , , ,Pronounced “cushy”, Cushe is a new ...
... Melanoma and other ... linked to cancer risk. Practical and clinical information about skin health, melanoma and skin cancer ... , ... With skin cancer on the rise for Americans under 30 and indoor tanning contributing to ...
... ... ... the MTA is keeping some residents in Brooklyn up at night. Meg Richichi has been calling ... attorneys in New York are familiar with the compromise between construction safety and convenience., , ...
... ... Coral Gables (Miami) Florida, Medical Equipment Solutions has been providing services ... Their experts have a passion for helping customers improve their quality ... and oxygen concentrators, the specialists at MES have the experience to ...
Cached Medicine News:Health News:Overtime Boosts Heart Attack Risk 2Health News:Overtime Boosts Heart Attack Risk 3Health News:Conflict Boss Brings Sanity Back to the Workplace and Lets Managers Get Back to Managing 2Health News:Onlineshoes.com and Cushe Team Up to Offer Men and Women Shoes for Casual Living 2Health News:Onlineshoes.com and Cushe Team Up to Offer Men and Women Shoes for Casual Living 3Health News:Skincancer.com Launches With Latest News, Information and Help for Consumers/Patients and Physicians 2Health News:Skincancer.com Launches With Latest News, Information and Help for Consumers/Patients and Physicians 3Health News:New York Construction Accident Attorney, David Perecman, Supports MTA Night Work 2Health News:Miami's Medical Equipment Solutions Now Offers Electric Power Wheelchair 2Health News:Miami's Medical Equipment Solutions Now Offers Electric Power Wheelchair 3Health News:Miami's Medical Equipment Solutions Now Offers Electric Power Wheelchair 4Health News:Miami's Medical Equipment Solutions Now Offers Electric Power Wheelchair 5
Make better prescribing decisions with this drug interaction analyzer containing over 3,000 brand names with generic equivalents....
... Guide for Physicians - ... Integrated Calculators - combines ... and practical drug resource ... dosing calculation tools for ...
AnesthesiaDrugs™ is the handheld version of Sota Omoigui's Anesthesia Drugs Handbook, the best selling clinical guide to essential anesthesia and critical care drug information....
... drug information reference that integrates ... patient care guidelines., The sixth ... 4,700 drugs, including the latest ... indications, dosages, side effects and ...
Medicine Products: